scholarly journals Make Precision Medicine Work for Chronic Kidney Disease

2016 ◽  
Vol 26 (2) ◽  
pp. 101-107 ◽  
Author(s):  
Ling Sun ◽  
Lu-Xi Zou ◽  
Mao-Jie Chen
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Precision Medicine

scholarly journals Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant

2019 ◽  
Vol 171 (9) ◽  
pp. 659 ◽  
Author(s):  
Y. Dana Neugut ◽  
Sumit Mohan ◽  
Ali G. Gharavi ◽  
Krzysztof Kiryluk
Keyword(s):  
Chronic Kidney Disease ◽  
Genetic Testing ◽  
Kidney Disease ◽  
Precision Medicine

scholarly journals Willingness to Participate in a National Precision Medicine Cohort: Attitudes of Chronic Kidney Disease Patients at a Cleveland Public Hospital

2018 ◽  
Vol 8 (3) ◽  
pp. 21 ◽  
Author(s):  
Jessica Cooke Bailey ◽  
Dana Crawford ◽  
Aaron Goldenberg ◽  
Anne Slaven ◽  
Julie Pencak ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Precision Medicine ◽  
Public Hospital ◽  
Willingness To Participate

GSTM1 Gene, Diet, and Kidney Disease: Implication for Precision Medicine?: Recent Advances in Hypertension

Hypertension ◽  
2021 ◽  
Author(s):  
Thu H. Le
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Precision Medicine ◽  
Disease Progression ◽  
Angiotensin Receptor Blockers ◽  
The United States ◽  
Cruciferous Vegetables ◽  
Related Factor ◽  
Environment Interaction

In the United States, the prevalence of chronic kidney disease in adults is ≈14%. The mainstay of therapy for chronic kidney disease is angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, but many patients with chronic kidney disease still progress to end-stage kidney disease. Increased oxidative stress is a major molecular underpinning of chronic kidney disease progression. In humans, a common deletion variant of the glutathione-S-transferase μ-1 ( GSTM1 ) gene, the GSTM1 null allele ( GSTM1(0 )), results in decreased GSTM1 enzymatic activity and is associated with higher levels of oxidative stress. GSTM1 belongs to the superfamily of GSTs that are phase II antioxidant enzymes and are regulated by Nrf2 (nuclear factor erythroid 2-related factor 2). Cruciferous vegetables in general, and broccoli in particular, are rich in glucoraphanin, a precursor of sulforaphane that has been shown to have protective effects against oxidative damage through the activation of Nrf2. This review will highlight recent human and animal studies implicating the role of GSTM1 deficiency in hypertension and kidney disease, and its impact on the effects of cruciferous vegetables on kidney injury and disease progression, illustrating the significance of gene and environment interaction and a potential for targeted precision medicine in the treatment of kidney disease.

Sign in / Sign up

Export Citation Format

Share Document